COVID-19: Which Drug, When, and Why? Monoclonal Antibody Treatments

Source: COVID-19: Which Drug, When, and Why?
In which patients with COVID-19 should we use monoclonal antibodies as prophylaxis or treatment? Hear expert insights on the timing and role of monoclonal antibody treatments for COVID-19 during the omicron era.
Gregory Huhn, MD, MPHTM
Released: April 21, 2022

The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:

  • Bebtelovimab
  • Cilgavimab/tixagevimab
  • Sotrovimab

Information on this Educational Activity

Faculty

Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Gregory Huhn, MD, MPHTM, has disclosed that he has received funds for research support from Lilly and consulting fees from Gilead Sciences, Janssen, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings